Azacyclic bisphosphonates as anticholesterolemic agents
AssigneeRhone-Poulenc Rorer Pharmaceuticals Inc.
InventorsJohn W. Ullrich, Raymond D. Youssefyeh, Daniel L. Cheney, Christopher J. Burns
Life of this patent
Estimating the term…
Abstract
This invention relates to a method of lowering abnormally high serum cholesterol levels in the body without significantly reducing mevalonic metabolite synthesis and to novel pharmacological compositions containing as an active ingredient bisphosphonic acid and ester compounds containing a mono-, bi- or tricyclic ring linked with a bisphosphonate moiety through a basic amino alkylene group. This invention also provides novel bisphosphonate compounds and the processes for their preparation.
Claims9
A method of lowering serum cholesterol or maintaining lowered serum cholesterol in a patient requiring such treatment which comprises administering to such patient a squalene synthetase inhibitor effective amount of a compound selected from the group consisting of:
- 3-[3-azabicyclo[3.2.2]non-3-yl]-1-hydroxypropylidene-1,1-bisphosphonic acid, which is ##STR57## 3-[adamant-2-ylamino]-1-hydroxypropylidene-1,1-bisphosphonic acid, which is ##STR58## or 3-[norborn-2-ylamino]-1-hydroxypropylidene-1,1-bisphosphonic acid, which is ##STR59## or a pharmaceutically acceptable salt thereof.
A method of lowering serum cholesterol or maintaining lowered serum cholesterol in a patient requiring such treatment which comprises administering to such patient a squalene synthetase inhibitor effective amount of a compound selected from the group consisting of:
- 3-[1-azacyclohept-1-yl]-1-hydroxypropylidene-1,1-bisphosphonic acid, which is ##STR60## 3-[piperidin-1-yl]-1-hydroxypropylidene-1,1-bisphosphonic acid, which is ##STR61## 3-[N-decahydroquinolinyl]-1-hydroxypropylidene-1,1-bisphosphonic acid, which is ##STR62## or 3-[4-phenylpiperidin-1-yl]-1-hydroxypropylidene-1,1-bisphosphonic acid, which is ##STR63## or a pharmaceutically acceptable salt thereof.
A method of lowering serum cholesterol or maintaining lowered serum cholesterol in a patient requiring such treatment which comprises administering to such patient a squalene synthetase inhibitor effective amount of a compound selected from the group consisting of:
- 3-[1-indanylamino]-1-hydroxypropylidene-1,1-bisphosphonic acid, which is ##STR64## or 3-[1,2,3,4-tetrahydronaphth-1-ylamino]-1-hydroxy-propylidine-1,1-bisphosph onic acid, which is ##STR65## or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.